Literature DB >> 9971797

Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.

M J Martiney1, L S Levy, J Lenz.   

Abstract

The transcriptional enhancer of the lymphomagenic mouse retrovirus SL3 contains a binding site for the transcription factor core binding factor (CBF; also called AML1, PEBP2, and SEF1). The SL3 CBF binding site is called the core. It differs from the core of the weakly lymphomagenic mouse retrovirus Akv by one nucleotide (the sequences are TGTGGTTAA and TGTGGTCAA, respectively). A mutant virus called SAA that was identical to SL3 except that its core was mutated to the Akv sequence was only moderately attenuated for lymphomagenicity. In most SAA-infected mice, tumor proviruses contained either reversions of the original mutation or one of two novel core sequences. In 20% of the SAA-infected mice, tumor proviruses retained the original SAA/Akv core mutation but acquired one of two additional mutations (underlined), TGCGGTCAA or TGTGGTCTA, that generated core elements called So and T*, respectively. We tested whether the novel base changes in the So and T* cores were suppressor mutations. SL3 mutants that contained So or T* cores in place of the wild-type sequence were generated. These viruses induced T-cell lymphomas in mice more quickly than SAA. Therefore, the mutations in the So and T* cores are indeed second-site suppressor mutations. The suppressor mutations increased CBF binding in vitro and transcriptional activity of the viral long terminal repeats (LTRs) in T lymphocytes to levels comparable to those of SL3. Thus, CBF binding was increased by any of three different nucleotide changes within the sequence of the SAA core. Increased CBF binding resulted in increased LTR transcriptional activity in T cells and in increased viral lymphomagenicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971797      PMCID: PMC104459     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

Authors:  P Erickson; J Gao; K S Chang; T Look; E Whisenant; S Raimondi; R Lasher; J Trujillo; J Rowley; H Drabkin
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

3.  Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers.

Authors:  B Corneliussen; A Thornell; B Hallberg; T Grundström
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.

Authors:  B Hallberg; J Schmidt; A Luz; F S Pedersen; T Grundström
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Authors:  Y Kamachi; E Ogawa; M Asano; S Ishida; Y Murakami; M Satake; Y Ito; K Shigesada
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design.

Authors:  E A Golemis; N A Speck; N Hopkins
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.

Authors:  A L Boral; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

9.  Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity.

Authors:  N A Speck; B Renjifo; E Golemis; T N Fredrickson; J W Hartley; N Hopkins
Journal:  Genes Dev       Date:  1990-02       Impact factor: 11.361

10.  Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers.

Authors:  S W Wang; N A Speck
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

View more
  5 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

4.  Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites.

Authors:  Chassidy Johnson; Patricia A Lobelle-Rich; Adriane Puetter; Laura S Levy
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.

Authors:  Karina Dalsgaard Sørensen; Leticia Quintanilla-Martinez; Sandra Kunder; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.